Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Plus, we note that GLP-1 drugs can increase a person’s risk of aspiration ... The drugs whose labels were updated include ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

A recent study found that semaglutide, a GLP-1 weight loss drug ... The trial was funded by Novo Nordisk, the company that makes semaglutide. “There is a significant need for non-surgical and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like Peptide (GLP-1) products, such as Ozempic, on the local ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

Sahpra warns of falsified diabetes treatments Ozempic and Mounjaro sold online for weight loss, posing health risks.

Conditions are getting a bit more challenging for the drugmaker.